We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
(+13%)
Cap. Flow
+$76.2M
Cap. Flow
% of AUM
1.6%
Top 10 Holdings %
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24
Avg Time Held
4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$190M |
| 2 |
Insmed
INSM
|
+$168M |
| 3 |
Gilead Sciences
GILD
|
+$130M |
| 4 |
United Therapeutics
UTHR
|
+$105M |
| 5 |
BridgeBio Pharma
BBIO
|
+$81.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Krystal Biotech
KRYS
|
+$121M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$82.6M |
| 3 |
Revolution Medicines
RVMD
|
+$72.5M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$70.4M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$63.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.91% |
| 2 | Miscellaneous | 0.05% |
| 3 | Technology | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Beta Bionics
BBNX
$927M
| $1.13M | 0.02% |
72,152
| – | – |
2025 Q1
5 quarters
|
|
102
Legend Biotech
LEGN
$3.6B
| $955K | 0.02% |
33,054
-2,832
| -8% | -$76.4K |
2020 Q4
22 quarters
|
|
103
Pfizer
PFE
$168B
| $925K | 0.02% |
38,431
-69,204
| -64% | -$1.81M |
2023 Q3
11 quarters
|
|
104
Abivax
ABVX
$7.66B
| $852K | 0.02% |
6,397
+5,349
| +510% | +$605K |
2026 Q1
1 quarter
|
|
105
Encompass Health
EHC
$12.6B
| $703K | 0.01% |
6,951
-2,878
| -29% | -$298K |
2023 Q4
10 quarters
|
|
106
Axsome Therapeutics
AXSM
$8.19B
| $658K | 0.01% |
2,689
-492
| -15% | -$107K |
2021 Q2
20 quarters
|
|
107
Certara
CERT
$1.42B
| $651K | 0.01% |
99,442
| – | – |
2023 Q3
11 quarters
|
|
108
AgomAb Therapeutics NV
AGMB
$411M
| $639K | 0.01% |
49,248
-752
| -2% | -$8.46K |
2026 Q1
1 quarter
|
|
109
Praxis Precision Medicines
PRAX
$6.79B
| $618K | 0.01% |
1,847
+90
| +5% | +$28.5K |
2026 Q1
1 quarter
|
|
110
Apple
AAPL
$5.01T
| $541K | 0.01% |
1,768
-1,552
| -47% | -$444K |
2025 Q3
3 quarters
|
|
111
Garmin
GRMN
$55.5B
| $469K | 0.01% |
1,976
+655
| +50% | +$159K |
2024 Q1
9 quarters
|
|
112
Denali Therapeutics
DNLI
$2.79B
| $457K | 0.01% |
17,766
| – | – |
2025 Q4
2 quarters
|
|
113
VanEck Gold Miners ETF
GDX
$26.1B
| $434K | 0.01% |
5,750
| – | – |
2024 Q4
6 quarters
|
|
114
Veradermics Inc
MANE
$4.56B
| $426K | 0.01% |
+3,468
| New | +$325K |
2026 Q2
0 quarters
|
|
115
Alphabet (Google) Class A
GOOGL
$4.17T
| $396K | 0.01% |
907
+593
| +189% | +$213K |
2025 Q1
5 quarters
|
|
116
Definium Therapeutics
DFTX
$4.33B
| $395K | 0.01% |
+8,391
| New | +$207K |
2026 Q2
0 quarters
|
|
117
Travere Therapeutics
TVTX
$4.71B
| $392K | 0.01% |
6,908
-1,991
| -22% | -$88.3K |
2025 Q4
2 quarters
|
|
118
Amazon
AMZN
$2.69T
| $383K | 0.01% |
1,605
+252
| +19% | +$63.3K |
2025 Q1
5 quarters
|
|
119
Halozyme
HALO
$13.8B
| $340K | 0.01% |
4,348
+491
| +13% | +$33.5K |
2026 Q1
1 quarter
|
|
|
120
Alnylam Pharmaceuticals
ALNY
$31.2B
| $329K | 0.01% |
1,092
-233,451
| -100% | -$70.4M |
2016 Q1
41 quarters
|
|
121
CRISPR Therapeutics
CRSP
$4.82B
| $317K | 0.01% |
5,818
+802
| +16% | +$42.3K |
2025 Q4
2 quarters
|
|
122
Structure Therapeutics
GPCR
$1.52B
| $256K | 0.01% |
4,762
-2,041
| -30% | -$90.3K |
2023 Q3
11 quarters
|
|
123
Viatris
VTRS
$21.1B
| $251K | 0.01% |
+15,778
| New | +$245K |
2026 Q2
0 quarters
|
|
124
Mineralys Therapeutics
MLYS
$1.8B
| $236K | 0.01% |
8,753
-20,621
| -70% | -$566K |
2024 Q1
9 quarters
|
|
125
Summit Therapeutics
SMMT
$11.8B
| $223K | ﹤0.01% |
15,279
-579
| -4% | -$10.3K |
2024 Q3
7 quarters
|
|
Similar funds
PTC
Bellevue Group's Q2 2026 Portfolio in Review
As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Technology.
- Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
- Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
- Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
- Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
- Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
- Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
- Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.
Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.